OBJECTIVE: Approximately half of older patients treated for major depressive disorder (MDD) do not achieve symptomatic remission and functional recovery with first-line pharmacotherapy. This study aims to characterize sociodemographic, clinical, and neuropsychologic correlates of full, partial, and non-response to escitalopram monotherapy of unipolar MDD in later life. METHODS: One hundred and seventy-five patients aged 60 and older were assessed at baseline on demographic variables, depression severity, hopelessness, anxiety, cognitive functioning, co-existing medical illness burden, social support, and quality of life (disability). Subjects received 10 mg/d of open-label escitalopram and were divided into full (n = 55; 31%), partial (n = 75; 42.9%), and non-responder (n = 45; 25.7%) groups based on Hamilton depression scores at week 6. Univariate followed by multivariate analyses tested for differences between the three groups. RESULTS: Non-responders to treatment were found to be more severely depressed and anxious at baseline than both full and partial responders, more disabled, and with lower self-esteem than full responders. In general partial responders resembled full responders more than they resembled non-responders. In multivariate models, more severe anxiety symptoms (both psychological and somatic) and lower self-esteem predicted worse response status at 6 weeks. CONCLUSION: Among treatment-seeking elderly persons with MDD, higher anxiety symptoms and lower self-esteem predict poorer response after six weeks of escitalopram treatment. Copyright 2007 John Wiley & Sons, Ltd.
OBJECTIVE: Approximately half of older patients treated for major depressive disorder (MDD) do not achieve symptomatic remission and functional recovery with first-line pharmacotherapy. This study aims to characterize sociodemographic, clinical, and neuropsychologic correlates of full, partial, and non-response to escitalopram monotherapy of unipolar MDD in later life. METHODS: One hundred and seventy-five patients aged 60 and older were assessed at baseline on demographic variables, depression severity, hopelessness, anxiety, cognitive functioning, co-existing medical illness burden, social support, and quality of life (disability). Subjects received 10 mg/d of open-label escitalopram and were divided into full (n = 55; 31%), partial (n = 75; 42.9%), and non-responder (n = 45; 25.7%) groups based on Hamilton depression scores at week 6. Univariate followed by multivariate analyses tested for differences between the three groups. RESULTS: Non-responders to treatment were found to be more severely depressed and anxious at baseline than both full and partial responders, more disabled, and with lower self-esteem than full responders. In general partial responders resembled full responders more than they resembled non-responders. In multivariate models, more severe anxiety symptoms (both psychological and somatic) and lower self-esteem predicted worse response status at 6 weeks. CONCLUSION: Among treatment-seeking elderly persons with MDD, higher anxiety symptoms and lower self-esteem predict poorer response after six weeks of escitalopram treatment. Copyright 2007 John Wiley & Sons, Ltd.
Authors: M A Dew; C F Reynolds; B Mulsant; E Frank; P R Houck; S Mazumdar; A Begley; D J Kupfer Journal: J Affect Disord Date: 2001-07 Impact factor: 4.839
Authors: H A Sackeim; R F Haskett; B H Mulsant; M E Thase; J J Mann; H M Pettinati; R M Greenberg; R R Crowe; T B Cooper; J Prudic Journal: JAMA Date: 2001-03-14 Impact factor: 56.272
Authors: Jordan F Karp; Daniel J Buysse; Patricia R Houck; Christine Cherry; David J Kupfer; Ellen Frank Journal: Am J Psychiatry Date: 2004-10 Impact factor: 18.112
Authors: Martha L Bruce; Thomas R Ten Have; Charles F Reynolds; Ira I Katz; Herbert C Schulberg; Benoit H Mulsant; Gregory K Brown; Gail J McAvay; Jane L Pearson; George S Alexopoulos Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds Journal: Drugs Aging Date: 2004 Impact factor: 3.923
Authors: Eric J Lenze; Benoit H Mulsant; M Katherine Shear; Patricia Houck; Charles F Reynolds III Journal: Drugs Aging Date: 2002 Impact factor: 3.923
Authors: Leslie Thomas; Benoit H Mulsant; Francis X Solano; Ann M Black; Salem Bensasi; Tracy Flynn; Jeffrey S Harman; Bruce L Rollman; Edward P Post; Bruce G Pollock; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2002 Sep-Oct Impact factor: 4.105
Authors: Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed Journal: Am J Geriatr Psychiatry Date: 2015-05-21 Impact factor: 4.105
Authors: Halina J Dour; Joshua F Wiley; Peter Roy-Byrne; Murray B Stein; Greer Sullivan; Cathy D Sherbourne; Alexander Bystritsky; Raphael D Rose; Michelle G Craske Journal: Depress Anxiety Date: 2013-12-12 Impact factor: 6.505
Authors: Adam Greenlee; Jordan F Karp; Mary Amanda Dew; Patricia Houck; Carmen Andreescu; Charles F Reynolds Journal: Depress Anxiety Date: 2010-05 Impact factor: 6.505
Authors: Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant Journal: Depress Anxiety Date: 2019-11-04 Impact factor: 6.505
Authors: Lynn M Martire; Richard Schulz; Charles F Reynolds; Jennifer Q Morse; Meryl A Butters; Gregory A Hinrichsen Journal: Psychol Aging Date: 2008-06